Yoon H, et al. - In this phase II study, researchers assessed panitumumab (Pa; a fully humanized IgG2 monoclonal antibody against human EGFR) plus irinotecan (Ir) as second-line therapy for advanced esophageal adenocarcinoma (EAC). They assessed response rate (RR) following administration of Pa 9 mg/m² on day 1 and Ir 125 mg/m² on days 1 and 8 of each 21-day cycle in patients with one prior treatment. Inclusion criteria were confirmed EAC, measurable disease, no prior Ir or Pa, performance status <2, and normal organ function. The observed partial response rate and clinical benefit (partial response [PR] plus stable disease [SD]) rate was 6% and 50%, respectively. The observed median overall survival and median progression-free survival was 7.2 months and 2.9 months, respectively. No complete remissions were reported. Overall, irinotecan and panitumumab as second-line treatment for advanced EAC were not active.